Oregon — In a move that aligns federal policy more closely with long-standing state experiments in cannabis regulation, the U.S. Department of Justice and Drug Enforcement Administration announced the immediate placement of FDA-approved marijuana-derived products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act. The action, taken under authority tied to the Single Convention on Narcotic Drugs, also launches an expedited administrative hearing process beginning June 29, 2026, to consider broader rescheduling of marijuana from Schedule I.
Acting Attorney General Todd Blanche framed the decision as fulfilling President Trump’s December 18, 2025, Executive Order on Increasing Medical Marijuana and Cannabidiol Research. “The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options,” Blanche said. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.” DEA Administrator Terry Cole added that the agency remains focused on combating drug cartels and the fentanyl epidemic while bringing “consistency and oversight” to a sector long hampered by federal-state misalignment.
For Oregon, one of the nation’s earliest and most established legal cannabis markets, the announcement arrives none too soon. Recreational marijuana has been regulated by the Oregon Liquor and Cannabis Commission (OLCC) since 2016, creating a robust, tax-paying industry that has tested the limits of free-market forces under heavy state oversight. As of late 2025, the state counted approximately 1,349 licensed producers (growers), 243 wholesalers (distributors), 770 retailers, and smaller numbers of processors and laboratories, a total of roughly 2,649 active recreational cannabis businesses.
Market Realities in the Beaver State
Oregon’s industry generated approximately $925 million in recreational sales in 2025, a modest 3.5 percent decline from the prior year amid persistent oversupply. Growers harvested a record 13 million pounds or more of cannabis flower, driving wholesale prices to historic lows and squeezing margins across the supply chain. Despite these pressures, emblematic of a competitive marketplace where supply has outpaced demand, the sector continues to deliver tangible economic benefits.
The industry supports more than 6,000 full-time Oregon jobs and has generated more than $1.3 billion in cumulative state tax revenue since legalization. Annual excise tax collections (at the 17 percent rate) have hovered in the $150–180 million range in recent years, directing funds to schools, mental health and addiction services, law enforcement, and local governments.
From a policy perspective, Oregon’s experience illustrates both the promise and pitfalls of state-led legalization. A free-market approach has fostered innovation and consumer choice, yet the combination of high state taxes, licensing fees, and regulatory hurdles has contributed to market saturation and consolidation. Smaller operators have struggled while larger, vertically integrated firms adapt. The federal rescheduling to Schedule III, which eases certain research barriers and potentially mitigates punitive federal tax treatment under Section 280E for qualifying medical operations, could provide breathing room without undermining the strict controls needed to prevent diversion to the illicit market.
Path Forward
The expedited hearing process and procedural updates to the rulemaking timeline signal a more efficient federal review than under the previous administration. A new notice of hearing will be published in the Federal Register, replacing earlier proceedings. Supporters in Oregon’s cannabis community view the changes as long-overdue recognition of state successes and a step toward reducing the regulatory friction that has sometimes favored black-market operators over licensed businesses.
Critics of broader federal liberalization will note the DEA’s continued emphasis on enforcement against cartels and fentanyl trafficking, priorities that remain unchanged. For Oregon growers and distributors, the immediate Schedule III placement of state-licensed medical products offers practical relief and research opportunities, while the broader hearing promises measured, evidence-based progress.
Under the DOJ/DEA action, state-licensed medical marijuana products (which many Oregon growers supply) move immediately into Schedule III. This acknowledges accepted medical use under state programs while the broader rescheduling hearing proceeds.
As the June 29 hearing approaches, Oregon’s cannabis economy stands as a case study in what happens when states lead and markets respond. The Trump administration’s actions suggest a pragmatic federal pivot: one that respects state authority, prioritizes patient access and scientific inquiry, and maintains vigilance against criminal enterprises, a balance that could help stabilize and strengthen one of the Pacific Northwest’s notable economic success stories.
About the Author
Discover more from Right Now Oregon
Subscribe to get the latest posts sent to your email.
